



Oceanaa Biotek Industries Limited  
IN:L15549TN2005PLC057919  
GSTIN: 33AAA 08057E1ZM  
E:obil@oceanaabiotek.com  
www.oceanaabiotek.com

OBIL/BSE/41/2019-2020

12<sup>th</sup> February, 2020

To,  
The Corporate Relations Department  
The Bombay Stock Exchange Ltd,  
P J Towers, 1<sup>st</sup> Floor,  
Dalal Street,  
Mumbai – 400 001

Dear Sir/Madam,

Ref: Scrip Code: **538019**

ISIN: **INE732P01018**

**Sub:** Submission of Standalone Unaudited Financial Results for the quarter and Nine months ended on 31<sup>st</sup> December, 2019.

This is to inform you that the meeting of the Board of Directors was held today, 12<sup>th</sup> February, 2020 inter alia, to consider and approve the Unaudited (limited reviewed) Financial Results for the quarter and Nine months ended on 31.12.2019.

In this regard, the following documents are enclosed herewith:

- Standalone Unaudited Financial Results for the quarter and Nine months ended on 31.12.2019 - Regulation 33 - Annexure I of SEBI (LODR) Regulations, 2015.
- Limited review report signed by the Statutory Auditor


The meeting commenced at 10:00 a.m. and concluded at 06:00 p.m.

Kindly update the above in your records.

Thanking You.

For Oceanaa Biotek Industries Limited

Xavier Jeyaraj  
Managing Director  
**Encl:** As above



**Limited Review Report for the Quarter Ending 31<sup>st</sup> December 2019**

To  
The Board of Directors  
M/s. OCEANAA BIOTEK INDUSTRIES LIMITED  
No.6, 1<sup>st</sup> Floor, Wellington Estate  
53, Ethiraj Salai, Egmore  
Chennai – 600008, Tamil Nadu.

We have reviewed the accompanying statement of Unaudited Financial Results, of M/s. OCEANAA BIOTEK INDUSTRIES LIMITED ("the Company") for the quarter ended 31<sup>st</sup> December, 2019 and year to date from April 01, 2019 to December 31, 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No. CIR/CFD/CM1/80/2019 dated 19<sup>th</sup> July, 2019 ("the Circular").


This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


For ABHAY JAIN & CO.  
Chartered Accountants  
FRN: 0000008S

Date: 12/02/2020  
Place: Chennai

  
(A.K. Jain)

M NO:070224

UDIN: 20070224AAAAAO3293



**M/S. OCEANAA BIOTEK INDUSTRIES LIMITED**  
CIN: L15549TN2005PLC057919  
Flat No. C-4, Ceebros Apartments, No. 2, Saravana Street, T Nagar, Chennai - 600017


**Unaudited Standalone Financial Results for the Quarter Ended 31st Dec 2019**

in lakhs except earnings per share and share information/data

S.No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	31-03-2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Revenue from Operations</b>						
	a) Sale of products	327.87	524.48	801.58	1,307.26	3,305.33	3,628.19
	b) Other Operating Revenues	-	-	-	-	-	-
	<b>Total Revenue from Operations</b>	<b>327.87</b>	<b>524.48</b>	<b>801.58</b>	<b>1,307.26</b>	<b>3,305.33</b>	<b>3,628.19</b>
<b>2</b>	<b>Other Income</b>	-	-	-	-	-	0.62
<b>3</b>	<b>Total Income (1+2)</b>	<b>327.87</b>	<b>524.48</b>	<b>801.58</b>	<b>1,307.26</b>	<b>3,305.33</b>	<b>3,628.81</b>
<b>4</b>	<b>Expenses</b>						
	a) Cost of Materials Consumed	106.69	-	469.62	268.94	1,860.68	2,645.57
	b) Purchase of Stock-in-Trade	-	171.28	-	171.28	-	-
	c) Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-Trade"	7.20	6.69	130.78	38.11	249.33	587.47
	d) Employee Benefits Expense	26.10	28.97	37.05	95.12	168.10	192.87
	e) Depreciation and Amortisation Expense	54.45	54.45	79.00	162.75	236.81	250.43
	f) Finance Costs	1.74	2.08	2.70	5.84	8.83	11.50
	g) Other Expenses	40.61	123.80	67.42	220.03	459.22	1,997.51
	<b>Total Expenses</b>	<b>236.79</b>	<b>387.27</b>	<b>786.57</b>	<b>962.08</b>	<b>2,982.97</b>	<b>5,685.35</b>
<b>5</b>	<b>Profit Before Exceptional Items and Tax (3 - 4)</b>	<b>91.08</b>	<b>137.22</b>	<b>15.01</b>	<b>345.19</b>	<b>322.36</b>	<b>(2,056.54)</b>
<b>6</b>	<b>Exceptional Items [Refer Note 4]</b>	-	-	-	-	-	-
<b>7</b>	<b>Profit Before Tax (5 + 6)</b>	<b>91.08</b>	<b>137.22</b>	<b>15.01</b>	<b>345.19</b>	<b>322.36</b>	<b>(2,056.54)</b>
<b>8</b>	<b>Tax Expense</b>						
	Current Tax	1.89	9.09	4.37	18.33	93.00	-
	Deferred Tax Asset/ (Liability)	(21.11)	(2.08)	(2.90)	(24.50)	(61.15)	(51.22)
	<b>Total</b>	<b>(19.21)</b>	<b>7.01</b>	<b>1.47</b>	<b>(6.16)</b>	<b>31.85</b>	<b>(51.22)</b>
<b>9</b>	<b>Profit After Tax (7 - 8)</b>	<b>110.29</b>	<b>130.20</b>	<b>13.54</b>	<b>351.35</b>	<b>290.51</b>	<b>(2,005.32)</b>
<b>10</b>	<b>Other Comprehensive Income</b>						
	"a) Items not to be reclassified to profit or loss in subsequent periods"	-	-	-	-	-	7.47
	"Re-measurement Gains and (Losses) on Defined Benefit Obligations (Net) and Net (Loss)/Gain on FVTOCI Equity Securities"	-	-	-	-	-	-
	Income Tax Effect	-	-	-	-	-	-
	"b) Items to be reclassified to profit or loss in subsequent periods"	-	-	-	-	-	-
	Net movement on cash flow hedges	-	-	-	-	-	-
	Income Tax Effect	-	-	-	-	-	-
	<b>Other Comprehensive Income for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>7.47</b>
<b>11</b>	<b>Total Comprehensive income (9 + 10)</b>	<b>110.29</b>	<b>130.20</b>	<b>13.54</b>	<b>351.35</b>	<b>290.51</b>	<b>(1,997.85)</b>
<b>12</b>	<b>Paid-up Equity Share Capital (Face Value of 10 Each)</b>	<b>135,652,750</b>	<b>135,652,750</b>	<b>135,652,750</b>	<b>135,652,750</b>	<b>135,652,750</b>	<b>135,652,750</b>
<b>13</b>	<b>Earnings Per Share (Face Value Rs. 10/- per Share) -</b>						
	- Basic (in Rs.)	0.81	0.96	0.10	2.59	2.14	(14.78)
	- Diluted (in Rs.)	0.81	0.96	0.10	2.59	2.14	(14.78)

**Notes:**

- The Audited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Sec 133 of the Companies Act'2013 and other recognised accounting practices and policies to the extent applicable.
- Figures of the previous period/year are reclassified /regrouped or rearranged wherever necessary to make it comparable.
- There are no separate reportable segments for the three months ended December 2019 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2014.
- There were no Investors' Complaints received during the period.
- All the financial numbers presented above are prepared as per the IND



For and on Behalf of Board of Directors

Thomas Xavier Jeyaraj  
Managing Director  
DIN: 06896574

Place: Chennai  
Date : 12-Feb-2020

To  
THE BOARD OF DIRECTORS,  
FLAT NO.C-4, CEEBROS APARTMENTS  
NO.2, SARAVANA STREET,  
T.NAGAR, CHENNAI-600017


Dear Sir/Madam,


We hereby confirm the following in respect of the unaudited financial statements for the quarter and nine months ended on 31<sup>st</sup> December, 2019 being presented before the Board at the meeting to be held on 12<sup>th</sup> February, 2020.

- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely

Place: Chennai  
Date: 12.02.2020



  
T Xavier Jeyaraj  
Managing Director  
DIN: 06896574




Date: 12th February, 2020


DECLARATION

M/s Abhay Jain & Co., Chartered Accountants, Statutory Auditors of the Company have given an unmodified opinion with respect to the Standalone unaudited Financial Results for the quarter and nine months ended on 31<sup>st</sup> December, 2019.


This declaration is submitted in compliance with Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation, 2016, as issued by SEBI vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May, 25, 2016.

For Oceanaa Biotek Industries Limited

  
Xavier Jeyaraj  
Managing Director  
Place: Chennai



For Abhay Jain & Co.,  
Chartered Accountants  
FRN: 00000085

  
CA A K JAIN  
Partner  
M No.: 070224

